María Dolores Martín‐Arranz
A5043396998- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Diverticular Disease and Complications
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Celiac Disease Research and Management
- Helicobacter pylori-related gastroenterology studies
- Diagnosis and treatment of tuberculosis
- Biosimilars and Bioanalytical Methods
- Gastric Cancer Management and Outcomes
- Pregnancy and Medication Impact
- Gastrointestinal disorders and treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- COVID-19 Clinical Research Studies
- Anorectal Disease Treatments and Outcomes
- Pancreatitis Pathology and Treatment
- Spondyloarthritis Studies and Treatments
- Mycobacterium research and diagnosis
- Liver Disease Diagnosis and Treatment
- Autoimmune and Inflammatory Disorders Research
- Colorectal Cancer Screening and Detection
- Gastroesophageal reflux and treatments
- SARS-CoV-2 and COVID-19 Research
Hospital Universitario La Paz
2016-2025
Universidad Autónoma de Madrid
2020-2025
Hospital La Paz Institute for Health Research
2019-2025
Clínica Santa María
2025
University Hospital Complex Of Vigo
2025
Hospital Universitario Fundación Jiménez Díaz
2019
AbbVie (Spain)
2018
Hospital Universitario de La Princesa
2014
Abstract Background Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by periods of relapse and remission. Current treatment options aim to achieve mucosal healing sustain long-term remission, yet many patients experience failure. Filgotinib (FIL), selective JAK1 inhibitor, has emerged as promising therapeutic agent in UC management with favorable outcomes clinical trials. This study aimed evaluate the real-world efficacy safety FIL moderate-to-severe UC. Methods We...
The aims of this study were to assess the risk relapse after discontinuation anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), identify factors associated relapse, and evaluate overcome retreatment same anti-TNF those who relapsed.This was a retrospective, observational, multicenter study. IBD had been treated anti-TNFs whom these discontinued clinical remission achieved included.A total 1,055 included. incidence rate 19% 17% per patient-year...
To evaluate the effectiveness and safety of tofacitinib in ulcerative colitis [UC] real life.Patients from prospectively maintained ENEIDA registry treated with due to active UC were included. Clinical activity defined based on Partial Mayo Score [PMS]. Short-term response/remission was assessed at Weeks 4, 8, 16.A total 113 patients They exposed for a median time 44 weeks. Response remission Week 8 60% 31%, respectively. In multivariate analysis, higher PMS 4 (odds ratio [OR] = 0].2; 95%...
The aims of this study were to determine the prevalence fatigue in patients with inflammatory bowel disease [IBD], identify factors associated and its severity, assess impact on quality life [QoL], evaluate relationship between sleep disorders.This was a prospective multicentre conducted at 22 Spanish centres. Consecutive followed IBD Units included. Fatigue evaluated Severity Scale [FSS] Impact [FIS]. Quality assessed using Questionnaire-Short Form [IBDQ-9] Pittsburgh Sleep Index [PSQI],...
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe main epidemiological and clinical characteristics at diagnosis evolution disease, explore use drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 Spain were included followed-up for 1 year. (3) Results: We identified 3611 incident cases during 108 hospitals...
Abstract Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety ustekinumab in Crohn’s disease (CD) patients real-world clinical practice. Methods A retrospective, multicentre study was conducted Spain with active CD who had received ≥1 intravenous dose for ≥6 months. Primary outcome retention rate; secondary outcomes were identify predictive factors drug retention, short-term remission (week 16), loss response efficacy...
Summary Background Pancreatitis is a potentially severe condition. Patients with inflammatory bowel disease (IBD) seem to be at increased risk for acute pancreatitis. Aim To describe the incidence, main causes and possible predictive factors of pancreatitis in disease. Methods Information was retrospectively extracted from clinical records patients followed IBD Units nine hospitals Madrid ( n = 5073). Results A total 82 episodes were diagnosed (cumulative 1.6%); 98% them mild. Recurrent...
Recently, the notion that smoking may adversely affect Crohn's disease (CD) outcomes has been challenged by suggestion widespread use of immunosuppressants and anti-TNF drugs might offset adverse effects tobacco.To reassess influence tobacco on phenotype complications a time-dependent analysis, taking into account different therapeutic interventions.We designed retrospective cohort study 3224 patients with disease. The data were collected from Spanish national inflammatory bowel registry...
Psoriasis induced by anti-tumor necrosis factor-α (TNF) therapy has been described as a paradoxical side effect.To determine the incidence, clinical characteristics, and management of psoriasis anti-TNF in large nationwide cohort inflammatory bowel disease patients.Patients with were identified from Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes genéticos y Ambientales registry Grupo Español de Trabajo Croh Colitis Ulcerosa....
Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis administered. Evidence for optimal treatment lacking. Our aim was to compare the efficacy adalimumab [ADA] and azathioprine [AZA] in this setting. We performed a phase 3, 52-week, multicentre, randomised, superiority study [APPRECIA], which patients with ileocolonic resection were randomised either ADA 160-80-40 mg subcutaneously [SC] or AZA 2.5 mg/kg/day, both associated metronidazole. The primary...
Summary Background Data on the long‐term administration of ustekinumab in recommended doses are limited. Aim To assess real‐world, effectiveness refractory Crohn's disease (CD). Methods Multi‐centre study CD patients starting at dose, followed for 1 year. Values Harvey‐Bradshaw Index (HBI), endoscopic activity, C‐reactive protein (CRP), and faecal calprotectin (FC) were recorded baseline weeks 26 52. Demographic clinical data, previous treatments, adverse events (AEs) hospitalisations...
Abstract Background and Aims Clinical trials real-life studies with ustekinumab in Crohn’s disease [CD] have revealed a good efficacy safety profile. However, these data are scarcely available elderly patients. Therefore, we aim to assess the effectiveness of patients CD. Methods Elderly [>60 years old] from prospectively maintained ENEIDA registry treated due CD were included. Every patient was matched two controls under 60 age, according anti-tumour necrosis factor use smoking...
Immunomodulators are used as maintenance treatment of inflammatory bowel disease (IBD). Data regarding their possible effects in the course pregnancy when father is exposed at time conception limited.To evaluate outcomes pregnancies which fathers were to thiopurines conception. A series male patients followed seven IBD clinics Madrid, Spain, was studied. Any exposure during 3 months preceding considered significant. Controls fathered by who either had never been treated with or interrupted...
Data regarding the effectiveness of adalimumab (ADA) in treatment perianal fistula patients with Crohn's disease (CD) naive to antitumor necrosis factor (TNF) therapy are scarce.: To assess ADA fistulas CD anti-TNF therapy.A retrospective multicenter study was designed. The Fistula Drainage Assessment Index used clinical response, and Van Assche Ng indexes classify radiologic response (magnetic resonance imaging).A total 46 (83% women, 83% complex fistula) were included. At 6 months, 72%...
Summary Background Thiopurines are the most widely used immunosuppressants in IBD although drug‐related adverse events (AE) occur 20%‐30% of cases. Aim To evaluate safety thiopurines elderly patients Methods Cohort study including all adult ENEIDA registry who received thiopurines. Patients were grouped terms age at beginning thiopurine treatment, specifically those started over 60 years or between 18 and 50 age. Thiopurine‐related AEs registered database compared. Results Out 48 752...
Abstract Background The effectiveness of the switch to another anti–tumor necrosis factor (anti-TNF) agent is not known. aim this study was analyze and safety treatment with a second third anti-TNF drug after intolerance or failure previous in inflammatory bowel disease (IBD) patients. Methods We included patients diagnosed IBD from ENEIDA registry who received prior agent. Results A total 1122 were included. In short term, remission achieved 55% anti-TNF. incidence loss response 19% per...
Abstract Background In inflammatory bowel disease, altered microbial states of the gut ecosystem could influence response to treatment. Our objective was investigate possibility predicting vedolizumab using markers microbiome. Methods To this end, we analysed characteristics microbiome shotgun metagenomic sequencing in 21 patients with active ulcerative colitis, eligible for treatment vedolizumab. The protocol included assessment clinical activity and analysis faecal samples prior at weeks...
Abstract Background Drug level monitoring is standard practice for anti-TNF therapies (1,2). In the case of vedolizumab, pivotal studies suggest a similar relationship (3,4) although real-world are needed. This study aimed to investigate between vedolizumab levels during induction phase and clinical response in medium long term. Methods A retrospective analysis was performed on cohort patients diagnosed with inflammatory bowel disease who completed at least IBD Unit Hospital La Paz(from...